Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/42048
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFokas, Emmanouil-
dc.contributor.authorRoedel, Claus-
dc.contributor.authorSmith, J. Joshua-
dc.contributor.authorGarcia-Aguilar, Julio-
dc.contributor.authorBUYSE, Marc-
dc.contributor.authorGlynne-Jones, Robert-
dc.date.accessioned2024-01-08T07:49:59Z-
dc.date.available2024-01-08T07:49:59Z-
dc.date.issued2023-
dc.date.submitted2024-01-05T14:56:58Z-
dc.identifier.citationLancet Gastroenterology & Hepatology, 8 (11) , p. 962 -964-
dc.identifier.urihttp://hdl.handle.net/1942/42048-
dc.language.isoen-
dc.publisherELSEVIER INC-
dc.rights2023 Elsevier Ltd. All rights reserved.-
dc.titleDisease-free survival as the endpoint in multimodal rectal cancer trials: have we got this right?-
dc.typeJournal Contribution-
dc.identifier.epage964-
dc.identifier.issue11-
dc.identifier.spage962-
dc.identifier.volume8-
local.format.pages3-
local.bibliographicCitation.jcatA2-
dc.description.notesFokas, E (corresponding author), Goethe Univ Frankfurt, Dept Radiotherapy Oncol, D-60590 Frankfurt, Germany.; Fokas, E (corresponding author), German Canc Res Ctr, Frankfurt, Germany.; Fokas, E (corresponding author), Frankfurt Canc Inst, Frankfurt, Germany.-
dc.description.notesemmanouil.fokas@kgu.de-
local.publisher.place525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA-
local.type.refereedRefereed-
local.type.specifiedEditorial Material-
local.classdsPublValOverrule/author_version_not_expected-
dc.identifier.doi10.1016/S2468-1253(23)00231-5-
dc.identifier.isi001122935100001-
local.provider.typewosris-
local.description.affiliation[Fokas, Emmanouil; Roedel, Claus] Goethe Univ Frankfurt, Dept Radiotherapy Oncol, D-60590 Frankfurt, Germany.-
local.description.affiliation[Fokas, Emmanouil; Roedel, Claus] German Canc Res Ctr, Frankfurt, Germany.-
local.description.affiliation[Fokas, Emmanouil; Roedel, Claus] Frankfurt Canc Inst, Frankfurt, Germany.-
local.description.affiliation[Smith, J. Joshua; Garcia-Aguilar, Julio] Mem Sloan Kettering Canc Ctr, Dept Surg, Colorectal Serv, New York, NY 10021 USA.-
local.description.affiliation[Buyse, Marc] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat, Diepenbeek, Belgium.-
local.description.affiliation[Buyse, Marc] Int Drug Dev Inst, San Francisco, CA USA.-
local.description.affiliation[Glynne-Jones, Robert] Mt Vernon Ctr Canc Treatment, Dept Radiotherapy, Northwood, Middx, England.-
local.uhasselt.internationalyes-
item.accessRightsClosed Access-
item.contributorFokas, Emmanouil-
item.contributorRoedel, Claus-
item.contributorSmith, J. Joshua-
item.contributorGarcia-Aguilar, Julio-
item.contributorBUYSE, Marc-
item.contributorGlynne-Jones, Robert-
item.fullcitationFokas, Emmanouil; Roedel, Claus; Smith, J. Joshua; Garcia-Aguilar, Julio; BUYSE, Marc & Glynne-Jones, Robert (2023) Disease-free survival as the endpoint in multimodal rectal cancer trials: have we got this right?. In: Lancet Gastroenterology & Hepatology, 8 (11) , p. 962 -964.-
item.fulltextNo Fulltext-
crisitem.journal.eissn2468-1253-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.